← The Wire·Consumer·

Ultragenyx (RARE) gains 7.5% on FDA approval of $2.7 million gene therapy

Ultragenyx shares jumped 7.5% after FDA approval of a gene therapy priced at $2.7 million, putting commercialization execution at the center of the story. The approval is a clear regulatory win, but the company still has to convert a high-priced treatment into durable revenue while carrying a -85.4% net margin.

STOCK PHOTO · MATHIAS REDING

The story

The FDA approval triggered a 7.5% move in Ultragenyx shares. The therapy carries a $2.7 million price tag, though the specific indication, launch timing, and FDA label details will be critical to assess the commercial opportunity.

Ultragenyx reported $673.0M of revenue for fiscal 2025, up 20.2% year over year, but its diluted EPS was $-5.83 and its net margin was -85.4%. The approved product therefore adds a potentially meaningful commercial opportunity to a business that is growing revenue but remains deeply unprofitable.

The next evidence should come from launch timing, payer coverage, treatment-center capacity, patient identification and early prescription or revenue disclosures. Management's first outlook for the therapy and the company's next earnings report will be important in determining whether the approval becomes a durable earnings driver rather than a one-day catalyst.

Our read · Tue, Aug 25

The FDA approval lifts the commercial ceiling for RARE, but the 7.5% jump runs into a $2.7 million pricing model and a -85.4% net margin that still require proof of uptake.

Why. The approval improves Ultragenyx's revenue opportunity, but the trade remains balanced because launch timing, reimbursement, patient volume, and the therapy's contribution to earnings remain uncertain. The company's $673.0M of fiscal 2025 revenue grew 20.2% year over year, yet the -85.4% net margin and $-5.83 diluted EPS leave commercialization execution as the decisive variable.

Both cases

The case it holdsThe strongest bull case is that FDA approval unlocks a high-value product alongside 20.2% year-over-year revenue growth, giving RARE a new path to scale beyond its $673.0M fiscal 2025 revenue base.
The case it breaksThe bear case is stronger on near-term execution risk, while RARE remains at a -85.4% net margin with $-5.83 diluted EPS after the approval-driven 7.5% move.

What could change this view: The read fails if early launch disclosures show strong payer access and treatment uptake that translate the $2.7 million price into revenue faster than expected.

Ultragenyx Pharmaceutical stock page →
Your side is graded privately against closes after 10 trading days. Research, not advice.

Who reported it · 1

Keep reading

Latest on the Wire

Greer says US chip curbs will close China export-control loopholesBlackRock bitcoin ETF posts $541.1 million outflow as tech sell-off spreadsPoland says Russian missiles and drone crashed during Ukraine assaultAnthropic debut fails to halt technology-led slide in US stocksUS MATCH Act puts ASML at center of China chip export disputeContinue on the Wire →

Top this week

Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic IPO could become the largest in US history on Thursday
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.

About this report

Reported by Yahoo Finance as Ultragenyx (RARE) Jumped 7.5% on FDA Approval. Can a $2.7 Million Gene Therapy Become a Commercial Success?, . Who answers for this

The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →

Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →